Selected research
Industry Research
Uric Acid-lowering Drugs Industry Research Report 2026
Market perspective
The global Uric Acid-lowering Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Uric Acid-lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Uric Acid-lowering Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Uric Acid-lowering Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Uric Acid-lowering Drugs include Takeda Pharmaceuticals, Teva, Sanwa Kagaku Kenkyusho, Sanofi, GSK, AstraZeneca, Towa Pharmaceutical, Toa Eiyo and Mylan Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Uric Acid-lowering Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Uric Acid-lowering Drugs Market by Company
Takeda Pharmaceuticals
Teva
Sanwa Kagaku Kenkyusho
Sanofi
GSK
AstraZeneca
Towa Pharmaceutical
Toa Eiyo
Mylan Pharmaceuticals
Mochida Pharmaceutical
Lannett Company
Horizon Therapeutics
Fuji Yakuhin
Uric Acid-lowering Drugs Segment by Type
Uric Acid Production Inhibitors
Uric Acid Dissolving Agents
Urate-stimulating Excretion Agents
Uric Acid-lowering Drugs Segment by Application
Hyperuricemia
Uric Acid Kidney Stones
Gout
Other
Uric Acid-lowering Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Uric Acid-lowering Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Uric Acid-lowering Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Uric Acid-lowering Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Uric Acid-lowering Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Uric Acid-lowering Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Uric Acid-lowering Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Uric Acid Production Inhibitors
- Uric Acid Dissolving Agents
- Urate-stimulating Excretion Agents
Applications
- Hyperuricemia
- Uric Acid Kidney Stones
- Gout
- Other
Companies covered
- Takeda Pharmaceuticals
- Teva
- Sanwa Kagaku Kenkyusho
- Sanofi
- GSK
- AstraZeneca
- Towa Pharmaceutical
- Toa Eiyo
- Mylan Pharmaceuticals
- Mochida Pharmaceutical
- Lannett Company
- Horizon Therapeutics
- Fuji Yakuhin
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Uric Acid-lowering Drugs Market Size (2021-2032)
- 2.2.2 Global Uric Acid-lowering Drugs Sales (2021-2032)
- 2.2.3 Global Uric Acid-lowering Drugs Market Average Price (2021-2032)
- 2.3 Uric Acid-lowering Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Uric Acid Production Inhibitors
- 2.3.3 Uric Acid Dissolving Agents
- 2.3.4 Urate-stimulating Excretion Agents
- 2.4 Uric Acid-lowering Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hyperuricemia
- 2.4.3 Uric Acid Kidney Stones
- 2.4.4 Gout
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Uric Acid-lowering Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Uric Acid-lowering Drugs Sales (Units) of Manufacturers (2021-2026)
- 3.3 Global Uric Acid-lowering Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Uric Acid-lowering Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Uric Acid-lowering Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Uric Acid-lowering Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Uric Acid-lowering Drugs, Product Type & Application
- 3.8 Global Manufacturers of Uric Acid-lowering Drugs, Established Date
- 3.9 Global Uric Acid-lowering Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda Pharmaceuticals
- 4.1.1 Takeda Pharmaceuticals Company Information
- 4.1.2 Takeda Pharmaceuticals Business Overview
- 4.1.3 Takeda Pharmaceuticals Uric Acid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Pharmaceuticals Uric Acid-lowering Drugs Product Portfolio
- 4.1.5 Takeda Pharmaceuticals Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Uric Acid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Uric Acid-lowering Drugs Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 Sanwa Kagaku Kenkyusho
- 4.3.1 Sanwa Kagaku Kenkyusho Company Information
- 4.3.2 Sanwa Kagaku Kenkyusho Business Overview
- 4.3.3 Sanwa Kagaku Kenkyusho Uric Acid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanwa Kagaku Kenkyusho Uric Acid-lowering Drugs Product Portfolio
- 4.3.5 Sanwa Kagaku Kenkyusho Recent Developments
- 4.4 Sanofi
- 4.4.1 Sanofi Company Information
- 4.4.2 Sanofi Business Overview
- 4.4.3 Sanofi Uric Acid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sanofi Uric Acid-lowering Drugs Product Portfolio
- 4.4.5 Sanofi Recent Developments
- 4.5 GSK
- 4.5.1 GSK Company Information
- 4.5.2 GSK Business Overview
- 4.5.3 GSK Uric Acid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GSK Uric Acid-lowering Drugs Product Portfolio
- 4.5.5 GSK Recent Developments
- 4.6 AstraZeneca
- 4.6.1 AstraZeneca Company Information
- 4.6.2 AstraZeneca Business Overview
- 4.6.3 AstraZeneca Uric Acid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AstraZeneca Uric Acid-lowering Drugs Product Portfolio
- 4.6.5 AstraZeneca Recent Developments
- 4.7 Towa Pharmaceutical
- 4.7.1 Towa Pharmaceutical Company Information
- 4.7.2 Towa Pharmaceutical Business Overview
- 4.7.3 Towa Pharmaceutical Uric Acid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Towa Pharmaceutical Uric Acid-lowering Drugs Product Portfolio
- 4.7.5 Towa Pharmaceutical Recent Developments
- 4.8 Toa Eiyo
- 4.8.1 Toa Eiyo Company Information
- 4.8.2 Toa Eiyo Business Overview
- 4.8.3 Toa Eiyo Uric Acid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Toa Eiyo Uric Acid-lowering Drugs Product Portfolio
- 4.8.5 Toa Eiyo Recent Developments
- 4.9 Mylan Pharmaceuticals
- 4.9.1 Mylan Pharmaceuticals Company Information
- 4.9.2 Mylan Pharmaceuticals Business Overview
- 4.9.3 Mylan Pharmaceuticals Uric Acid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Mylan Pharmaceuticals Uric Acid-lowering Drugs Product Portfolio
- 4.9.5 Mylan Pharmaceuticals Recent Developments
- 4.10 Mochida Pharmaceutical
- 4.10.1 Mochida Pharmaceutical Company Information
- 4.10.2 Mochida Pharmaceutical Business Overview
- 4.10.3 Mochida Pharmaceutical Uric Acid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Mochida Pharmaceutical Uric Acid-lowering Drugs Product Portfolio
- 4.10.5 Mochida Pharmaceutical Recent Developments
- 4.11 Lannett Company
- 4.11.1 Lannett Company Company Information
- 4.11.2 Lannett Company Business Overview
- 4.11.3 Lannett Company Uric Acid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Lannett Company Uric Acid-lowering Drugs Product Portfolio
- 4.11.5 Lannett Company Recent Developments
- 4.12 Horizon Therapeutics
- 4.12.1 Horizon Therapeutics Company Information
- 4.12.2 Horizon Therapeutics Business Overview
- 4.12.3 Horizon Therapeutics Uric Acid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Horizon Therapeutics Uric Acid-lowering Drugs Product Portfolio
- 4.12.5 Horizon Therapeutics Recent Developments
- 4.13 Fuji Yakuhin
- 4.13.1 Fuji Yakuhin Company Information
- 4.13.2 Fuji Yakuhin Business Overview
- 4.13.3 Fuji Yakuhin Uric Acid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Fuji Yakuhin Uric Acid-lowering Drugs Product Portfolio
- 4.13.5 Fuji Yakuhin Recent Developments
5 Global Uric Acid-lowering Drugs Market Scenario by Region
- 5.1 Global Uric Acid-lowering Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Uric Acid-lowering Drugs Sales by Region: 2021-2032
- 5.2.1 Global Uric Acid-lowering Drugs Sales by Region: 2021-2026
- 5.2.2 Global Uric Acid-lowering Drugs Sales by Region: 2027-2032
- 5.3 Global Uric Acid-lowering Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Uric Acid-lowering Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Uric Acid-lowering Drugs Revenue by Region: 2027-2032
- 5.4 North America Uric Acid-lowering Drugs Market Facts & Figures by Country
- 5.4.1 North America Uric Acid-lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Uric Acid-lowering Drugs Sales by Country (2021-2032)
- 5.4.3 North America Uric Acid-lowering Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Uric Acid-lowering Drugs Market Facts & Figures by Country
- 5.5.1 Europe Uric Acid-lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Uric Acid-lowering Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Uric Acid-lowering Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Uric Acid-lowering Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Uric Acid-lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Uric Acid-lowering Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Uric Acid-lowering Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Uric Acid-lowering Drugs Market Facts & Figures by Country
- 5.7.1 South America Uric Acid-lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Uric Acid-lowering Drugs Sales by Country (2021-2032)
- 5.7.3 South America Uric Acid-lowering Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Uric Acid-lowering Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Uric Acid-lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Uric Acid-lowering Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Uric Acid-lowering Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Uric Acid-lowering Drugs Sales by Type (2021-2032)
- 6.1.1 Global Uric Acid-lowering Drugs Sales by Type (2021-2032) & (Units)
- 6.1.2 Global Uric Acid-lowering Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Uric Acid-lowering Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Uric Acid-lowering Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Uric Acid-lowering Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Uric Acid-lowering Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Uric Acid-lowering Drugs Sales by Application (2021-2032)
- 7.1.1 Global Uric Acid-lowering Drugs Sales by Application (2021-2032) & (Units)
- 7.1.2 Global Uric Acid-lowering Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Uric Acid-lowering Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Uric Acid-lowering Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Uric Acid-lowering Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Uric Acid-lowering Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Uric Acid-lowering Drugs Value Chain Analysis
- 8.1.1 Uric Acid-lowering Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Uric Acid-lowering Drugs Production Mode & Process
- 8.2 Uric Acid-lowering Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Uric Acid-lowering Drugs Distributors
- 8.2.3 Uric Acid-lowering Drugs Customers
9 Global Uric Acid-lowering Drugs Analyzing Market Dynamics
- 9.1 Uric Acid-lowering Drugs Industry Trends
- 9.2 Uric Acid-lowering Drugs Industry Drivers
- 9.3 Uric Acid-lowering Drugs Industry Opportunities and Challenges
- 9.4 Uric Acid-lowering Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst